BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced on September 22, 2026 a second managed Medicare agreement for its fibromyalgia drug TONMYA, adding about 21 million Medicare lives. Medicare coverage for TONMYA now totals 32 million lives, or 58% of about 55 million Medicare lives in the U.S.
The agreement took effect immediately. By our calculation, it nearly triples earlier Medicare coverage: 32 million minus 21 million leaves about 11 million lives before the deal, roughly 20% of the Medicare population, against 58% now.
Total payer coverage for TONMYA reaches 53% of U.S. lives
Tonix says commercial and government coverage now totals about 166 million lives, 53% of about 314 million U.S. lives. Medicare accounts for about 19% of that total (32 million of 166 million). By our calculation, about 148 million lives, or 47%, remain outside coverage.
Tonix previously announced commercial agreements with two group purchasing organizations and one managed Medicare agreement. The company also says Medicaid covers TONMYA in nearly all states. It did not name the new Medicare payer or disclose TONMYA sales or prescription volumes.
Tonix raises its sales force by 50% to 150 representatives
Chief Commercial Officer Thomas Englese said about 50 new sales representatives are fully activated in the field, bringing the total to 150. That implies a prior force of about 100, so the field team has grown by 50%, by our calculation.
Englese said the company is focused on turning the new coverage into patient access across market access, sales and marketing. He said the Medicare agreement is expected to increase access to the drug.
TONMYA reaches second Medicare deal 13 months after FDA approval
The U.S. Food and Drug Administration approved TONMYA (cyclobenzaprine HCl sublingual tablets) on August 15, 2025, for fibromyalgia in adults. The Medicare agreement came about 13 months later. The company calls TONMYA the first new prescription medicine approved for fibromyalgia in more than 15 years.
CEO Seth Lederman describes TONMYA as a first-in-class, non-opioid analgesic designed for daily bedtime use in adults with fibromyalgia. He says the coverage agreements reflect the drug's value to patients and payers. Tonix says fibromyalgia affects more than 10 million U.S. adults.
Tonix says its patents are expected to give TONMYA U.S. market exclusivity until 2034, eight years after the September 2026 agreement.